GSK (LSE:GSK) fell 4.8% on Wednesday after a third-quarter update in which weaker vaccine sales overshadowed an otherwise decent set of numbers. Profit for the quarter fell, and sales of Shingrix and Arexvy came in below expectations. That was enough to outweigh better overall sales and earnings, and it left the shares as one of the larger decliners on the FTSE 100. GSK is one of Britain's biggest pharmaceutical companies, with businesses in vaccines, specialty medicines and treatments for conditions such as respiratory disease and HIV. Vaccines are a central pillar of the group. Shingrix is its shingles vaccine, while Arexvy is its vaccine against respiratory syncytial virus, and both are watched closely as growth drivers.

Against that backdrop, a shortfall in vaccine sales carries extra weight. Even though overall sales and earnings for the quarter were better than expected, investors focused on the area where the company had disappointed. Markets often punish a miss in a flagship category, because it raises questions about whether the most optimistic growth assumptions are still realistic.

The company also drew attention to its efforts to improve efficiency and its R&D ambitions. A £1.9 billion cost-saving programme and a push to advance its pipeline of new medicines were part of the message. Yet investors were unconvinced. Cost cuts can support profits, but they do not by themselves replace the revenue that might be lost if vaccine demand is softer than hoped.

That scepticism about the pipeline is understandable in a sector where the success of new drugs is uncertain and the timelines are long. Shareholders want evidence that future products can offset any slowdown in established franchises. On Wednesday, the update did not supply enough of that reassurance, and the selling followed.

GSK's decline came on a day when the broader market was only marginally higher. The FTSE 100 closed up 7.96 points, or 0.1%, at 10,694.50, supported by banks, which rose 1.1% as a group after the Budget raised their profit surcharge by less than feared. The FTSE 250 fell 0.3%. The Budget itself had little direct bearing on GSK, whose move was driven by its own results.

A single quarter does not settle the debate. Vaccine sales can be uneven from one period to the next, and a miss against expectations is not necessarily a sign of long-term decline. The company still posted better overall sales and earnings than anticipated, and the savings programme may help over time. But the market reaction showed how sensitive the shares are to the performance of the vaccines business.

Large pharmaceutical groups are judged on a balance between today's products and tomorrow's. Established vaccines provide cash flow now, while the pipeline is the promise of growth later, and a wobble in one tends to magnify doubts about the other. Efficiency programmes can bridge the gap for a while, but investors usually want evidence that the underlying demand and the R&D effort are both heading in the right direction.

For GSK (LSE:GSK), the immediate task is to persuade investors that vaccine demand will recover and that its pipeline can deliver. Until then, the shares may remain sensitive to every update on Shingrix and Arexvy. The coming weeks should show whether the vaccines shortfall proves a temporary stumble or a lasting drag, and whether management can convince shareholders that its cost savings and pipeline progress will translate into steadier growth over the longer term. Until that evidence arrives, the stock is likely to stay sensitive to each fresh data point from the vaccines franchise, and to any news from the R&D pipeline that could change the picture. Patience is a feature of the pharmaceutical sector, but it is rarely unlimited.